Abrdn PLC Repligen Corp Transaction History

Abrdn PLC

$57.3 Billion
Q2 2025

A detailed history of Abrdn PLC transactions in Repligen Corp stock. As of the latest transaction made, Abrdn PLC holds 46,178 shares of RGEN stock, worth $6.78 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

46,178

Holding current value

$6.78 Million

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 24, 2025	BUY	$108.89 - $145.23 $5.03 Million - $6.71 Million	46,178 New	46,178 $5.74 Million
Q2 2024 Aug 09, 2024	BUY	$120.0 - $182.95 $49,440 - $75,375	412 Added 8.05%	5,531 $697,000
Q1 2024 May 08, 2024	SELL	$170.78 - $208.42 $12,466 - $15,214	-73 Reduced 1.41%	5,119 $941,000
Q4 2023 Jan 31, 2024	BUY	$114.17 - $185.35 $8,106 - $13,159	71 Added 1.39%	5,192 $933,000
Q3 2023 Nov 06, 2023	BUY	$138.78 - $176.51 $5,273 - $6,707	38 Added 0.75%	5,121 $814,000
Q2 2023 Jun 20, 2024	BUY	$138.42 - $180.31 $188,804 - $245,942	1,364 Added 36.68%	5,083 $719,000
Q2 2023 Aug 04, 2023	BUY	$138.42 - $180.31 $188,804 - $245,942	1,364 Added 36.68%	5,083 $719,000
Q1 2023 Jun 20, 2024	SELL	$154.26 - $198.1 $215,964 - $277,340	-1,400 Reduced 27.35%	3,719 $626,000
Q1 2023 Apr 28, 2023	BUY	$154.26 - $198.1 $573,692 - $736,733	3,719 New	3,719 $626,000

Others Institutions Holding RGEN

# of Institutions

511

Shares Held

58.1M

Call Options Held

89.3K

Put Options Held

679K

Black Rock Inc. New York, NY

7.57M
Shares

$1.11 Billion
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

6.6M
Shares

$970 Million
0.09% of portfolio
Vanguard Group Inc Valley Forge, PA

5.08M
Shares

$746 Million
0.01% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

1.91M
Shares

$281 Million
0.53% of portfolio
State Street Corp Boston, MA

1.62M
Shares

$238 Million
0.01% of portfolio

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.15B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.

Account